Immunology: immune response as leading protection factor against cancer
https://doi.org/10.18027/2224-5057-2016-2-5-14
Abstract
The prospect of effective immunotherapies for the treatment of patients with cancer is now becoming a clinical reality. A basic understanding of interaction between the tumor and the immune system, immune regulation pathways, mechanisms of escape from immune control allows to identify and implement new therapeutic approaches for cancer treatment. This review provides a modern view on the formation of anti-tumor immunity. The role of the key players are discussed – the components of innate and adaptive immunity, the mechanisms of the immune response and their features.
About the Authors
Ksenia Andreevna Sarantseva
FGBU (Federal State Budgetary Institution) N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
post-graduate student
Russian Federation
post-graduate student
Ludmila Valentinovna Laktionova
Federal Research Clinical Center of the Specialized Types of Health Care and Medical Technologies FMBA of Russia
Russian Federation
Russian Federation
MD, PhD, DSc, professor, chief doctor
Elena Valer’evna Reutova
FGBU (Federal State Budgetary Institution) N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
MD, PhD, senior staff scientist
Russian Federation
MD, PhD, senior staff scientist
Polina Andreevna Chernenko
FGBU (Federal State Budgetary Institution) N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, PhD, research fellow
Valery Vladimirovich Breder
FGBU (Federal State Budgetary Institution) N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, PhD leading research scientist
References
1. Beck G. and Habicht G. S. Immunity and the Invertebrates. Scientific American. 1996; p. 6–66.
2. Litman G. W. Sharks and the Origins of Vertebrate Immunity. Scientific American. 1996; p. 67–71.
3. Хаитов Р. М., Игнатьева Г. А., Сидорович И. Г. Иммунология. Норма и патология. Москва, Медицина, 2010, 750 с. Haitov R. M., Ignateva G. A., Sidorovich I. G. Immunologiya. Norma i patologiya. Moskva, Meditsina, 2010, 750 s.
4. Janeway C. A. Jr, Travers P., Walport M. et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York: Garland Science; 2001.
5. Duquesnoy R. J., Trucco M. Genetic basis of cell surface polymorphisms encoded by the major histocompatibility complex in humans. Crit Rev Immunol. 1988; 8(2):103.
6. Medzhitov R., Janeway C. A. Jr. Innate immunity: impact on the adaptive immune response. Curr. Opin. Immunol. 1997; 9: 4–9.
7. Plackett T. P., Boehmer E. D., Faunce D. E., Kovacs E. J. Aging and innate immune cells. J Leukoc Biol, 2004; 76: 291–299.
8. Vivier E. et al. Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science. 2011; 331 (6013): 44–49.
9. Terunuma H. et al. Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. International Reviews of Immunology. 2008; 27 (3): 93–110.
10. Arina A. et al. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opinion on Biological Therapy. 2007; 5 (5): 599–615.
11. Dahlgren C. and Karlsson A. Respiratory burst in human neutrophils. Journal of Immunological Methods. 1999; 232 (1–2): 3–14.
12. Plowden J., Renshaw-Hoelscher M., Engleman C., Katz J., Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell. 2004; 3:161–167.
13. Blander J. M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006; 440: 808.
14. Banchereau J., Steinman R. M. Dendritic cells and the control of immunity. Nature. 1998; 392: 245.
15. Smith C. M. et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. 2004;5: 1143.
16. Мейл Д., Бростофф Д., Рот Д., Ройтт А. Иммунология. 7 (оригинальное). Москва: Логосфера, 2007–105–568 с. Meyl D., Brostoff D., Rot D., Roytt A. Immunologiya. 7 (originalnoe). Moskva: Logosfera, 2007–105–568 s.
17. Mauri C., Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30: 221–41.
18. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004 Jan; 4(1):11–22.
19. Coulie P. G., Van den Eynde B. J., van der Bruggen P., Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat.Rev Cancer 2014; 14:135–46.
20. Schreiber R. D., Old L. J., Smyth M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331: 1565–70.
21. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008; 27:5869–85.
22. Taube J. M., Anders R. A., Young G. D., Xu H., Sharma R., McMiller T.L. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra37.
23. Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252–64.
24. Le Mercier I., Chen W., Lines J. L., Day M., Li J., Sergent P. et al. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res. 2014; 74:1933–44.
25. DeFranco A., Locksley R. M., Robertson M. Immunity. The immune response in infectious and inflammatory disease. London, 2007, Ch. 12: 208–299.
26. Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22; 12(4):252–64.
27. Drake C. G., Jaffee E., Pardoll D. M. Mechanisms of immune evasion by tumors. Adv Immunol. 2006; 90:51–81.
28. Vesely M. D., Kershaw M. H., Schreiber R. D., Smyth M. J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011; 29:235–71.
29. Хаитов Р. М. Иммунология 2-е издание, 2013, 528 с. Haitov R. M. Immunologiya 2-e izdanie, 2013, 528 s.
30. Zhang L., Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J. Cell. Physiol. 2007; 211 (3): 590–597.
31. Horne Z. D., Jack R., Gray Z. T., Siegfried J. M., Wilson D. O. et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res. 2011 Nov; 171(1):1–5.
32. Coussens L. M., Zitvogel L., Palucka A. K. Neutralizing tumorpromoting chronic inflammation: A magic bullet? Science. 2013; 339:286–291.
Review
For citations:
Sarantseva K.A., Laktionova L.V., Reutova E.V., Chernenko P.A., Breder V.V. Immunology: immune response as leading protection factor against cancer. Malignant tumours. 2016;(2):5-14. (In Russ.) https://doi.org/10.18027/2224-5057-2016-2-5-14
Views:
2119
Email this article 